Pfizer Inc. PFE said late Wednesday that the Food and Drug Administration approved its respiratory syncytial virus vaccine Abrysvo for older adults. The drug maker said the FDA approved Abrysvo for use in adults 60 years of age or older. RSV is a contagious virus that attacks the lungs and breathing passages, and is considered a common cause of respiratory illness globally, Pfizer said, adding the vaccine will be available in the third quarter before RSV season in the fall. Back in February, the vaccine gained the slight backing of an FDA advisory panel, which makes non-binding recommendations to the agency. Earlier in…
